Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/carboplatin with or without PF-3512676 in first-line advanced NSCLC
2005-004555-35Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of agatolimod in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Oct 2005; status: terminated.
02
Drugs
agatolimod
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-004555-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004555-35.